No business profile yet.
Size Pharming (PHARM.AS) is a Netherlands Health Care company (Pharmaceuticals: Major) with a market value of $867M, the 50th largest of 60 Netherlands companies the cockpit tracks. Shares closed at €1.12 on 18 Nov 2026.
Performance Over six months the shares fell 5.8%, against -26.0% for the median peer and -4.8% for the Netherlands market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 1.7% over the last twelve months (peer median +3.2%); the operating margin is 8.9% (peer median -0.8%).
Valuation It trades at 34.9× forward earnings against a peer median of 24.7× (2nd most expensive of 7).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.6 points above its cost of capital (5.0% WACC).
Credit Pharming has 1 bond outstanding ($111M).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €333M | €333M | €275M | €227M | €196M |
| Revenue growth | — | +21% | +21% | +16% | — |
| Gross profit | €276M | €283M | €232M | €193M | €175M |
| EBITDA | €40.1M | €28.0M | €6.82M | -€10.2M | €12.0M |
| Net income | €20.9M | €2.53M | -€10.9M | -€9.76M | €13.0M |
| Free cash flow | €23.7M | €43.3M | -€6.49M | -€20.9M | €16.0M |
| Capital expenditure | €751,596 | €668,983 | €735,885 | €1.35M | €1.88M |
| Total debt | €101M | €98.6M | €108M | €155M | €156M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PHARM.AS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.9% | -11.6% | highest of 21 |
| 6-month return | -5.8% | -26.0% | 3rd highest of 19 |
| Distance from 52-week high | -38.6% | -43.7% | 8th highest of 21 |
| Revenue growth (TTM) | +1.7% | +3.2% | 10th highest of 19 |
| Operating margin | 8.9% | -0.8% | 5th highest of 19 |
| Forward P/E | 34.9× | 24.7× | 2nd most expensive of 7 |
| Growth the price implies (Req g, 7 yrs) | 2.4% | 18.6% | 3rd least demanding of 7 |
| Growth delivered (Del g) | +12.4% | +1.7% | 2nd highest of 7 |
| Hurdle (Req g minus delivered) | -10.0 pp | +10.2 pp | 2nd least demanding of 7 |
| ROIC minus cost of capital | +6.6 pp | -2.9 pp | 2nd highest of 15 |
| EV / EBITDA | 18.1× | 8.8× | 2nd most expensive of 6 |
| Net debt / EBITDA | -1.6× | -0.3× | 2nd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 34.9× | 2.4% | +12.4% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | n/a | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 38.3× | 31.7% | +4.2% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 28.1× | 17.7% | +22.7% |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 21.4× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 9.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 14.0× | -4.2% | +10.6% |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | n/a | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 29.0× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
Pharming has 1 bond outstanding with $111M face value.